69 related articles for article (PubMed ID: 2855874)
1. Immunological aspects of B-cell derived tumors in humans and rodents.
Klein G
Princess Takamatsu Symp; 1988; 19():3-13. PubMed ID: 2855874
[TBL] [Abstract][Full Text] [Related]
2. Forward and reverse changes in Ig/myc translocation carrying tumors.
Klein G
Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
[TBL] [Abstract][Full Text] [Related]
3. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
Klein G
Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
[TBL] [Abstract][Full Text] [Related]
4. Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
Klein G
Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
Klein G
AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
[TBL] [Abstract][Full Text] [Related]
6. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
7. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
[TBL] [Abstract][Full Text] [Related]
8. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
9. Conditioned tumorigenicity of activated oncogenes.
Klein G; Klein E
Cancer Res; 1986 Jul; 46(7):3211-24. PubMed ID: 3011242
[TBL] [Abstract][Full Text] [Related]
10. Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.
Pokrovskaja K; Ehlin-Henriksson B; Bartkova J; Bartek J; Scuderi R; Szekely L; Wiman KG; Klein G
Cell Growth Differ; 1996 Dec; 7(12):1723-32. PubMed ID: 8959341
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of nucleoskeleton- and cytoskeleton-associated proteins in Burkitt lymphoma-derived and Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Szekely L; Pokrovskaja K; Klein G
Cell Growth Differ; 1997 May; 8(5):599-609. PubMed ID: 9149911
[TBL] [Abstract][Full Text] [Related]
12. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.
Yokochi T; Holly RD; Clark EA
J Immunol; 1982 Feb; 128(2):823-7. PubMed ID: 6274961
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.
Rooney CM; Rickinson AB; Moss DJ; Lenoir GM; Epstein MA
IARC Sci Publ; 1985; (60):249-64. PubMed ID: 2998992
[TBL] [Abstract][Full Text] [Related]
14. Chromosomal translocations in B-cell derived tumors.
Klein G
Princess Takamatsu Symp; 1986; 17():159-70. PubMed ID: 3332008
[TBL] [Abstract][Full Text] [Related]
15. The etiology of Burkitt's lymphoma and the history of the shaken dogmas.
de Thé G
Blood Cells; 1993; 19(3):667-73; discussion 674-5. PubMed ID: 8018947
[TBL] [Abstract][Full Text] [Related]
16. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
17. The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.
Steel CM; Morten JE; Foster E
IARC Sci Publ; 1985; (60):265-92. PubMed ID: 2998993
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
19. Role of LMP1 in immune control of EBV infection.
Pai S; Khanna R
Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
[TBL] [Abstract][Full Text] [Related]
20. CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.
Kryworuckho M; Diaz-Mitoma F; Kumar A
Immunology; 1995 Sep; 86(1):41-8. PubMed ID: 7590880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
